Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term changes in BMD and serum calcium after romosozumab in postmenopausal osteoporosis
jRCT1040190111Recruiting
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of romosozumab in osteoporosis. Primary endpoint: Bone mineral density change at 6 months. Started Jan 2020; status: recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT1040190111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040190111.